You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》美銀證券下調藥明康德(02359.HK)目標價至120.2元 評級「買入」
美銀證券發表評報告指,藥明康德(02359.HK)上半年總收入177.56億元人民幣,按年增68.5%;惟毛利率由上年同期36.9%降至36.2%,主因位於上海新建成的臨港基地產能使用率不足,影響細胞及基因療法CTDMO業務(ATU),拖累毛利表現。公司應佔利潤達46.36億元人民幣,按年增73.3%。扣除非經營項目後,經調整後非國際財務報告準則淨利潤為43億元人民幣,按年增75.7%,大致上符合該行預期。 該行表示,與新冠病毒相關項目,成為公司今年的重要收入,而相關項目於明年的能見度較低,故該行將公司明年收入預測下調至463.53億元人民幣,即按年增19.6%,經調整後的非國際財務報告準則利潤預測則下調至111.07億元人民幣,按年增21.1%。 該行將其目標價由144.1元下調120.2元,重申評級「買入」。(ca/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account